Form 4: PTC Therapeutics EVP Sells Shares for Tax Obligations

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, sold shares of common stock on January 6 and 7, 2026, to cover tax withholding obligations related to RSU vesting.

Summary

• Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, Inc. (PTCT), reported two sales of common stock.
• On January 6, 2026, 1,340 shares were sold at $76.95 per share. This sale was to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units (RSUs) from a January 3, 2025 grant of 20,000 RSUs.
• On January 7, 2026, an additional 642 shares were sold at $77.48 per share. This sale was also for tax withholding purposes, linked to the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs.
• Following these transactions, Golden beneficially owns 93,294 shares of PTC Therapeutics common stock directly.
• Both transactions were made pursuant to an irrevocable sell to cover election, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The reported transactions are routine 'sell to cover' sales by an executive to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs). These are pre-planned transactions under Rule 10b5-1(c) and do not reflect a discretionary decision by the executive regarding the company's future prospects.

Positives

• The underlying vesting of Restricted Stock Units (RSUs) represents a form of executive compensation, indicating the executive is receiving equity as part of their remuneration package.
• The transactions were executed under a Rule 10b5-1(c) plan, which demonstrates pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• The sales reduce the direct beneficial ownership of common stock by a key executive, though the reason is non-discretionary (tax withholding).

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction for an executive of a publicly traded biotechnology company. Such 'sell to cover' transactions are common in the industry when executives' equity compensation (like RSUs) vests, as they are required to pay taxes on the vested shares.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice across industries, including biotechnology, for executives to manage tax liabilities arising from equity compensation vesting.
• The use of a Rule 10b5-1 plan for these sales aligns with best practices for insider trading compliance, demonstrating pre-planning and reducing the perception of opportunistic trading, similar to practices at comparable companies like Amgen or Gilead Sciences.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine, non-discretionary sales for tax purposes and do not signal a change in management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The reported transactions are routine 'sell to cover' sales by an executive to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs). These are pre-planned transactions under Rule 10b5-1(c) and do not reflect a discretionary decision by the executive regarding the company's future prospects. Therefore, they do not provide a basis for changing an investment recommendation.

Keywords

PTC Therapeutics, PTCT, Form 4, insider transaction, stock sale, RSU vesting, executive compensation, Lee Scott Golden, Rule 10b5-1